Stockscreener 앱 받기
8.96
4.27%
-0.40
시장 영업 전:
9.00
0.04
+0.45%
전일 마감가:
$9.36
열려 있는:
$9.47
하루 거래량:
5.12M
Relative Volume:
1.20
시가총액:
$2.30B
수익:
$503.49M
순이익/손실:
$-53.47M
주가수익비율:
-34.46
EPS:
-0.26
순현금흐름:
$-26.89M
1주 성능:
-9.59%
1개월 성능:
-16.65%
6개월 성능:
+19.15%
1년 성능:
+44.98%
1일 변동 폭
$8.92
$9.47
1주일 범위
$8.92
$10.07
52주 변동 폭
$6.015
$11.31
바이오크리스트 Stock (BCRX) Company Profile
명칭
Biocryst Pharmaceuticals Inc
전화
919-859-1302
주소
4505 EMPEROR BOULEVARD, DURHAM, NC
BCRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
8.96 | 2.30B | 503.49M | -53.47M | -26.89M | -0.26 |
|
RGC
Regencell Bioscience Holdings Ltd
|
17.04 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
155.95 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.37 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.46 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.76 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
바이오크리스트 Stock (BCRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-02-25 | 개시 | Wedbush | Outperform |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-09-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-13 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-02-22 | 업그레이드 | Needham | Hold → Buy |
| 2022-11-02 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-08-05 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-08-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-04-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-04-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-10 | 개시 | Oppenheimer | Outperform |
| 2021-08-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-03-01 | 개시 | Cowen | Outperform |
| 2020-09-29 | 재개 | JP Morgan | Overweight |
| 2020-06-17 | 개시 | BTIG Research | Neutral |
| 2020-05-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-15 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | 재개 | Piper Jaffray | Overweight |
| 2018-08-08 | 재개 | JP Morgan | Overweight |
| 2018-07-17 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | 개시 | Seaport Global Securities | Neutral |
| 2018-01-02 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | 개시 | Barclays | Equal Weight |
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-09-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2017-02-16 | 개시 | Ladenburg Thalmann | Buy |
| 2016-08-12 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 재확인 | FBR Capital | Outperform |
| 2016-02-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2016-02-09 | 다운그레이드 | Needham | Buy → Hold |
모두보기
바이오크리스트 주식(BCRX)의 최신 뉴스
Are Medical Stocks Lagging Acurx Pharmaceuticals (ACXP) This Year? - Nasdaq
BioCryst Stockholders Approve Stock Incentive Plan Amendment - TipRanks
BioCryst reports long-term efficacy of ORLADEYO in HAE treatment By Investing.com - Investing.com South Africa
Orladeyo approved in Colombia to prevent HAE swelling attacks - Angioedema News
BioCryst reports long-term efficacy of ORLADEYO in HAE treatment - Investing.com Australia
BioCryst (BCRX) Showcases Promising Results for ORLADEYO in HAE Treatment | BCRX Stock News - GuruFocus
BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI | BCRX Stock News - GuruFocus
BioCryst Presents New Data on the Long-term Efficacy and - GlobeNewswire
ORLADEYO Clinical Trial Results: 86% Attack Reduction Transforms Life for HAE Patients of All Ages - Stock Titan
Sector Update: Health Care Stocks Lean Lower Premarket Friday - MarketScreener
BioCryst Pharmaceuticals, Inc. Announces National Institute of Drug and Food Surveillance Grants Approval for Oral, Once-Daily ORLADEYO - marketscreener.com
Colombia approves BioCryst’s oral HAE treatment ORLADEYO By Investing.com - Investing.com Canada
BCRX: BioCryst's ORLADEYO Approved in Colombia for HAE Preventio - GuruFocus
BioCryst Pharmaceuticals Receives Approval for Orladeyo in Colombia - marketscreener.com
BCRX: BioCryst's ORLADEYO Approved in Colombia for HAE Prevention | BCRX Stock News - GuruFocus
ORLADEYO® (berotralstat) Approved in Colombia | BCRX Stock News - GuruFocus
ORLADEYO® (berotralstat) Approved in Colombia - GlobeNewswire
Orladeyo approved for reimbursement in the Netherlands - Angioedema News
Marburg Virus Disease Pipeline 2025: Therapies Under - openPR.com
BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis: A 46.47% Upside Potential Amidst Strong Revenue Growth - DirectorsTalk Interviews
BioCryst at Goldman Sachs Conference: Strategic Growth and Profitability By Investing.com - Investing.com Nigeria
BioCryst at Goldman Sachs Conference: Strategic Growth and Profitability - Investing.com Australia
Transcript : BioCryst Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - MarketScreener
California State Teachers Retirement System Boosts Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Wellington Management Group LLP - Defense World
Netherlands approves BioCryst’s HAE drug ORLADEYO for reimbursement By Investing.com - Investing.com South Africa
BioCryst Pharmaceuticals' Hereditary Angioedema Drug Approved for Reimbursement in Netherlands - MarketScreener
BioCryst (BCRX) Gains Approval in Netherlands for ORLADEYO | BCR - GuruFocus
Netherlands approves BioCryst’s HAE drug ORLADEYO for reimbursement - Investing.com Australia
BioCryst Achieves Reimbursement for ORLADEYO Across All Major European Countries - MarketScreener
BioCryst (BCRX) Gains Approval in Netherlands for ORLADEYO | BCRX Stock News - GuruFocus
BioCryst Achieves Reimbursement for ORLADEYO Across all Major Eu - GuruFocus
BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries | BCRX Stock News - GuruFocus
BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries - GlobeNewswire
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
New Strong Buy Stocks for June 4th - MSN
Orladeyo effective in HAE patients of different ages, data show - Angioedema News
BioCryst at Jefferies Conference: Promising Pipeline and Financial Growth By Investing.com - Investing.com South Africa
Transcript : BioCryst Pharmaceuticals, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 04 - marketscreener.com
BioCryst at Jefferies Conference: Promising Pipeline and Financial Growth - Investing.com
BioCryst Pharmaceuticals (BCRX) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Best Momentum Stock To Buy For June 4th - Barchart.com
biocryst pharmaceuticals extends cfo consulting agreement By Investing.com - Investing.com South Africa
Best Momentum Stock to Buy for June 4th - TradingView
biocryst pharmaceuticals extends cfo consulting agreement - Investing.com
BioCryst Extends Consulting Agreement with Former CFO - TipRanks
BioCryst Pharmaceuticals Inc (BCRX) Shares Up 3.59% on Jun 3 - GuruFocus
BioCryst (BCRX) Awards Restricted Stock Units to New Employees | - GuruFocus
BioCryst (BCRX) Awards Restricted Stock Units to New Employees | BCRX Stock News - GuruFocus
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BCRX Stock News - GuruFocus
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
바이오크리스트 (BCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.07%
0.22%
자본화:
|
볼륨(24시간):